Acer Therapeutics Inc. (Nasdaq: ACER), today announced that Acer’s management team will virtually present at, and participate in, the upcoming Gilmartin Group Emerging Growth Company Showcase and H.C. Wainwright 24th Annual Global Investment Conference.
NEWTON, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will virtually present at, and participate in, the upcoming Gilmartin Group Emerging Growth Company Showcase and H.C. Wainwright 24th Annual Global Investment Conference.
Conference: Gilmartin Group Emerging Growth Company Showcase
Format: Recorded corporate presentation
Date and Time: Recorded presentation available at 10:30 am ET, August 31, 2022
Register: https://gilmartin-emerging-growth-conference.open-exchange.net/registration
Webcast:https://kvgo.com/corporate-services/acer-therapeutics-aug-2022
Conference: H.C. Wainwright 24th Annual Global Investment Conference
Format: On-demand recorded corporate presentation and one-on-one virtual meetings
Date and Time: On-demand corporate presentation available beginning at 7 am ET, September 12, 2022
Webcast:https://journey.ct.events/view/09133963-6072-4f07-864c-3ed9b50db443
About Acer Therapeutics Inc.
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four investigational programs: ACER-001 (sodium phenylbutyrate) for treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced Vasomotor Symptoms (iVMS); EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, Zika, dengue, Ebola and COVID-19. For more information, visit www.acertx.com.
Corporate and IR Contact
Jim DeNike
Acer Therapeutics Inc.
jdenike@acertx.com
+1-844-902-6100
Nick Colangelo
Gilmartin Group
nick@gilmartinIR.com
+1-332-895-3226
